Loading...
XNAS
SXTC
Market cap165mUSD
Dec 04, Last price  
1.43USD
1D
0.70%
1Q
-11.18%
IPO
-99.99%
Name

China SXT Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:SXTC chart
P/E
P/S
95.31
EPS
Div Yield, %
Shrs. gr., 5y
100.83%
Rev. gr., 5y
-19.54%
Revenues
2m
-9.73%
3,718,6054,881,5237,019,2437,012,0265,162,2684,777,5732,602,2811,971,6791,928,4971,740,907
Net income
-3m
L+6.62%
141,5441,185,1461,187,5811,539,227-10,287,872-2,748,183-5,736,095-5,934,772-3,098,532-3,303,652
CFO
-2m
L+21.64%
182,472293,0421,920,161239,192934,247-1,316,561268,293-80,757-1,928,053-2,345,333

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
IPO date
Jan 04, 2019
Employees
88
Domiciled in
CN
Incorporated in
VG

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT